Geron Corp (GERN)

[Joda]

The Imetelstat (IMET) Dilemma, and the JNJ/Janssen (JNJ) Partnership
Investors, in general, have avoided Geron's stock for numerous reasons that have been discussed in detail. Geron is now a JNJ partner, and the IMET team (Janssen-Mayo-Geron) is deep and strong financially, medically, and scientifically. Geron's problems of the past are gone, and IMET's excellent future seems assured. We are all waiting for Dr. Tefferi's presentation in Istanbul, representing the team.

1. IMET has passed every test that it has been given, and Mayo Clinic has shown that it safe and effective in MF (Tantamount to a Cure).

2. JNJ, as a Geron, partner, is setting up global trials to show the "power" of IMET (24 weeks, comparison with Jakafi)

3. The needs of the patients have the top priority for everyone including the FDA and similar organizations worldwide.

4. The basket of blood cancer cousins all appear to be responding sucessfully to IMET (MF, MDS, AML) alone and with combination drugs (including JNJ's own).